Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sildenafil: a urologist's view.

M A Khan1, D P Mikhailidis, R J Morgan

  • 1Department of Urology, Royal Free and University College Medical School (University College London), Royal Free Campus and Royal Free Hampstead NHS Trust, London, UK.

Current Medical Research and Opinion
|May 2, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Endocrine Disorders and Peripheral Arterial Disease - A Series of Reviews Cushing Syndrome-Cortisol Excess.

Current vascular pharmacology·2023
Same author

Growth Hormone, Atherosclerosis and Peripheral Arterial Disease: Exploring the Spectrum from Acromegaly to Growth Hormone Deficiency.

Current vascular pharmacology·2023
Same author

Nonalcoholic Fatty Pancreas Disease: Role in Metabolic Syndrome, "Prediabetes," Diabetes and Atherosclerosis.

Digestive diseases and sciences·2021
Same author

Multifocal arterial disease: clinical implications and management.

Current opinion in cardiology·2020
Same author

Preface.

Current vascular pharmacology·2018
Same author

Daylight saving time and myocardial infarction: should we be worried? A review of the evidence.

European review for medical and pharmacological sciences·2018
Same journal

Treatment patterns among pediatric and adult patients with ulcerative colitis in the United States: a retrospective cohort study.

Current medical research and opinion·2026
Same journal

Multidrug-resistant <i>Pseudomonas aeruginosa</i> in Jordan: epidemiology, trends, determinants, and clinical outcomes.

Current medical research and opinion·2026
Same journal

RSV disease and vaccination knowledge, attitudes, and practices among US adults: a 2024-2025 RSV season survey.

Current medical research and opinion·2026
Same journal

Clinical and healthcare resource utilization outcomes following revision knee arthroplasty with and without a gradually reducing radius revision knee system.

Current medical research and opinion·2026
Same journal

Medication adherence measurement methods and their reported relationship with medication safety outcomes: a scoping review.

Current medical research and opinion·2026
Same journal

BMI response to dapagliflozin with or without semaglutide across obesity classes: a real-world observational study conducted in Saudi Arabia.

Current medical research and opinion·2026
See all related articles

Erectile dysfunction (ED) is a common condition. Sildenafil (Viagra) has significantly impacted ED treatment, offering an oral alternative to injections, with considerations for cardiovascular risk factors.

Area of Science:

  • Urology
  • Cardiology
  • Pharmacology

Background:

  • Erectile dysfunction (ED) is a prevalent condition with diverse causes.
  • Intracavernosal injections revolutionized ED treatment approximately 20 years ago.
  • Oral medications represent a significant advancement in ED management.

Purpose of the Study:

  • To review clinical trials involving sildenafil for erectile dysfunction.
  • To examine the impact of sildenafil on ED treatment paradigms.
  • To assess cardiovascular risk factors in patients with ED treated with sildenafil.

Main Methods:

  • Literature review of clinical trials on sildenafil for ED.
  • Analysis of treatment outcomes and patient responses.
  • Evaluation of cardiovascular risk profiles in the context of ED and sildenafil use.

Related Experiment Videos

Main Results:

  • Sildenafil (Viagra) has emerged as a major advancement in oral ED treatment.
  • The drug offers a convenient and effective alternative to previous therapies.
  • Cardiovascular risk factors are an important consideration in the management of ED patients.

Conclusions:

  • Sildenafil has transformed the therapeutic landscape for erectile dysfunction.
  • Oral sildenafil provides a significant treatment option for men with ED.
  • Understanding and managing cardiovascular risks is crucial for patients undergoing ED treatment with sildenafil.